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Motivation: In this study, a method is reported to perform IMRT and VMAT treat-
ment delivery veriﬁcation using 3D volumetric primary beam ﬂuences reconstructed
directly from planned beam parameters and treatment delivery records. The goals of
this paper are to demonstrate that 1) 3D beam ﬂuences can be reconstructed efﬁ-
ciently, 2) quality assurance (QA) based on the reconstructed 3D ﬂuences is capable
of detecting additional treatment delivery errors, particularly for VMAT plans,
beyond those identiﬁable by other existing treatment delivery veriﬁcation methods,
and 3) QA results based on 3D ﬂuence calculation (3DFC) are correlated with QA
results based on physical phantom measurements and radiation dose recalculations.
Methods: Using beam parameters extracted from DICOM plan ﬁles and treatment
delivery log ﬁles, 3D volumetric primary ﬂuences are reconstructed by forward-pro-
jecting the beam apertures, deﬁned by the MLC leaf positions and modulated by
beam MU values, at all gantry angles using ﬁrst-order ray tracing. Treatment deliv-
ery veriﬁcations are performed by comparing 3D ﬂuences reconstructed using beam
parameters in delivery log ﬁles against those reconstructed from treatment plans.
Passing rates are then determined using both voxel intensity differences and a 3D
gamma analysis. QA sensitivity to various sources of errors is deﬁned as the
observed differences in passing rates. Correlations between passing rates obtained
from QA derived from both 3D ﬂuence calculations and physical measurements are
investigated prospectively using 20 clinical treatment plans with artiﬁcially intro-
duced machine delivery errors.
Results: Studies with artiﬁcially introduced errors show that common treatment
delivery problems including gantry angle errors, MU errors, jaw position errors,
collimator rotation errors, and MLC leaf position errors were detectable at less
than normal machine tolerances. The reported 3DFC QA method has greater
sensitivity than measurement-based QA methods. Statistical analysis-based
Spearman’s correlations shows that the 3DFC QA passing rates are signiﬁcantly
correlated with passing rates of physical phantom measurement-based QA
methods.
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Conclusion: Among measurement-less treatment delivery veriﬁcation methods, the
reported 3DFC method is less demanding than those based on full dose re-calcula-
tions, and more comprehensive than those that solely checks beam parameters in
treatment log ﬁles. With QA passing rates correlating to measurement-based pass-
ing rates, the 3DFC QA results could be useful for complementing the physical
phantom measurements, or verifying treatment deliveries when physical measure-
ments are not available. For the past 4+ years, the reported method has been imple-
mented at authors’ institution 1) as a complementary metric to physical phantom
measurements for pretreatment, patient-speciﬁc QA of IMRT and VMAT plans, and
2) as an important part of the log ﬁle-based automated veriﬁcation of daily patient
treatment deliveries. It has been demonstrated to be useful in catching both treat-
ment plan data transfer errors and treatment delivery problems.
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1 | INTRODUCTION
In intensity-modulated radiotherapy (IMRT)1 and volumetric-modu-
lated arc therapy (VMAT),2 radiation is delivered in many individual
beam apertures of varying intensities to achieve highly conformal dose
distributions to the planning target volume (PTV), that minimize dose
to nearby health tissues.3 During delivery, mechanical parameters (e.g.,
MU, dose rate, gantry angle, collimator angle, jaw position and MLC
leaf positions) are synchronized to planned values, speciﬁed by control
points (CP).4 Given the complexity of these treatments, quality assur-
ance (QA) for treatment delivery is essential in detecting various types
of delivery failures in order to ensure the accuracy of a patient’s
dosimetry and safety. IMRT/VMAT QA can be performed using point
dose and planar dose measurements obtained via physical phantoms,
2D beam ﬂuences, and dose recalculations based on machine delivery
log ﬁles.4–6 In comparison to conventional measurement-based QA,
QA using log ﬁles offers various advantages including sampling higher
spatial and temporal resolutions, not requiring measurement devices
or phantoms, providing QA for fractional deliveries to patients, and
being readily automated.5,6 Performing IMRT QA using log ﬁles has
been claimed to be more effective and efﬁcient than, and complemen-
tary to, physical dose measurement-based QA.7–12 A major, ongoing
debate in the medical physics community is whether IMRT QA using
log ﬁles can replace conventional measurement-based methods.5
Numerous reports on using log ﬁles for IMRT/VMAT QA have
been presented in literature.13–18 Logged beam parameters can be
compared to planned values based on a relatively simple value-to-
value comparison. Dose recalculations that incorporate parameters
recorded in log ﬁles can verify the accuracy of delivered dose. Com-
putation time has been signiﬁcantly reduced with GPU accelera-
tion;19–23 however, comparing dose distributions can be complicated
by differences in dose calculation engines and treatment planning
systems (TPS), the accuracy of electron density determined in the
daily patient localization cone-beam CT images, and other factors.
Traditionally in IMRT QA, veriﬁcation of delivered 2D ﬂuence
maps for individual beams has been widely used.8 Two-dimensional
beam ﬂuence can be directly measured with various dosimeters
including diode or ion chamber arrays, e.g., MapCheck (Sun Nuclear,
Melbourne, FL, USA) or MatriXX (IBA, Bartlett, TN, USA), or even
with onboard electronic portal imaging devices (EPID).4,24,25 Beam
2D ﬂuence can also be digitally and proximately reconstructed from
treatment plan parameters or LINAC machine log ﬁles by integrating
across a beam aperture multiplied by the per-segment beam
MU.10,26–28 At the authors’ institution, 2D beam ﬂuences digitally
reconstructed from the DICOM plans and treatment delivery log ﬁles
have enabled detection of many errors for IMRT plans, including
human operating mistakes (resulting in wrong plans, wrong beams,
or wrong beam parameters), ﬂawed and suboptimal treatment plans
(containing undeliverable or incorrect machine parameters), data
transfer problems (resulting from unintended parameter changes),
and other minor false positive errors.11 However, for the case of
VMAT QA, such 2D beam ﬂuence veriﬁcation per beam angle may
not be appropriate because instantaneous beam aperture errors for
VMAT deliveries were signiﬁcant (up to 15%) for highly modulated
plans even though MLC leaves were well-within tolerances.29 A
composite 2D ﬂuence for a VMAT beam at a ﬁxed gantry angle
could be computed,30 but error detection using such ﬂuence is sub-
optimal due to the ignored gantry rotation. We therefore were moti-
vated to develop an alternative 3D ﬂuence calculation QA method,
i.e., 3DFC, that (1) could be more sensitive to detect certain delivery
machine errors (such as gantry rotation errors), (2) could provide
enhanced visualization of beam delivery discrepancies respective to
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the tumor target geometry, and (3) could infer correlations between
random treatment delivery discrepancies to dose discrepancies.
In this study, a simple and efﬁcient QA method based on 3D ﬂu-
ence calculation is reported. This method enables rapid calculation of
3D ﬂuences using beam parameters from machine log ﬁles and
DICOM plan ﬁles. Our goal is not to replace traditional physical
phantom measurement-based QA or a full-scale dose calculation, but
rather to present a simpler, complimentary solution for detecting
potential delivery machine parameters errors and plan parameter
transfer errors with improved 3D visualization. The reported 3DFC
QA method mainly focuses on checking delivery errors of machine
parameters — instead of scrutinizing TPS commissioning errors —
while potentially improving error sensitivities comparing to the tradi-
tional QA methods. Toward this goal, we examine correlations
between the resultant passing rates from our reported 3DFC QA
and conventional measurement-based QA in detail.
2 | MATERIALS AND METHODS
2.1 | Data
To calculate and verify the 3D ﬂuence volume, both the planned
beam parameters from DICOM plans and the reported beam param-
eters from the beam delivery log ﬁles are used. Beam parameters
are deﬁned similarly in the DICOM plans and machine log ﬁles. In
DICOM plans, beam parameters are deﬁned in control points, which
are checkpoints for the treatment machines to synchronize beam
parameters. For example, a control point deﬁnes the gantry, collima-
tor, jaw, and MLC leaf positions, as well as the accumulated beam
monitor units (MU) up to this control point. In machine log ﬁles,
each record stores the same beam and dosimetric parameters mea-
sured at ﬁxed intervals throughout delivery. The currently supported
machine log ﬁles are pre-TrueBeam dynamic MLC log ﬁles (dynalog)
and TrueBeam trajectory log ﬁles, both of which are acquired on
Varian linear accelerators. Records are generated every 50 and 20
milliseconds for pre-TrueBeam and TrueBeam machines, respec-
tively. TrueBeam trajectory logs also give absolute beam MUs and
dose rate, while dynalog ﬁles only give relative beam MU values.31
To be concise, only the TrueBeam trajectory log ﬁles and VMAT
plans will be discussed in the following sections.
2.2 | 3D ﬂuence calculation (3DFC)
Two-dimensional beam ﬂuence can be digitally computed based from
machine log ﬁles by integrating the per-segment beam aperture multi-
plied by the per-segment beam MU.10 In contrast, the 3D volumetric
ﬂuence is calculated by forward-projecting beam apertures, modulated
by beam monitor units (MU), at all beam angles. In this paper, 2D and
3D ﬂuence calculation methods are referred to as 2DFC and 3DFC,
respectively, and IMRT and VMAT delivery QA using 2DFC and 3DFC
methods are referred to as 2DFC QA and 3DFC QA, respectively.
Consider a point r~2 X, where Ω is the target 3D ﬂuence volume
around the beam isocenter. x, y and z represent coordinates of the point
r~with the origin deﬁned at the beam isocenter, the 3D ﬂuence intensity
Iðr~Þ is calculated, using the beam parameters in the machine log ﬁles, as:
Iðr~Þ ¼
Z
Fðr~0ðtÞÞ Mðr~0ðtÞÞ  _DðtÞ  SAD
2
jr~ s~ðtÞj dt (1)
where t is the delivery time, F is the 2D beam intensity proﬁle in air,
_D is the dose rate in MU/s, SAD is the source-to-axis distance, s~ðtÞ is
the source position, and M is the beam aperture mask with M = 1 if
r~0 is inside the beam aperture or M = 0 otherwise. Iðr~Þ represents
the total MU delivered to the point r~ by the cumulative beam aper-
ture the entire beam delivery. It is important to note that beam
attenuation and scattering are not considered as opposed to the dose
calculation in this simple approximation. The computed 3D ﬂuence is
essentially the dose in air. X-ray generated is approximated from the
single radiation source at the X-ray target, and the secondary effec-
tive source is not considered. As the mask is not binary in reality, but
a function of the aperture size, the ﬂuence for smaller apertures is
reduced due to the shadowing of the distributed secondary source
by the MLC. Therefore, we note that an approximation to the real
mask counterpart is applied in this calculation.
r~0 is the point r~ projected on the beam portal at 100 cm SAD
and couch, gantry and collimator are all at 0°:
r~0ðu;wÞ ¼ RcolðhÞP½RgðbÞRcouchðaÞr~ (2)
where Rcouch, Rg, and Rcol are the couch, gantry, and collimator rota-
tion matrices, respectively, and a, b, and h are the beam couch, gan-
try, and collimator angles, respectively. P is a 3D-to-2D projection
operator that projects a 3D coordinate r~ðx; y; zÞ to a point r~0ðu;wÞ
within the beam portal according to:









where u is oriented along the direction of the X-jaws (or MLC
motion), and w is given along the direction of the Y-jaws.
The beam aperture mask M is directly calculated using the jaw and
MLC leaf position data. For the projected point r~0 on the beam portal at
(u, w), the corresponding leaf pair number can be calculated using w.
The calculation is different for different machine conﬁgurations. For a
Varian Millennium 120 MLC module that has 60 MLC leaf pairs, the
leaf widths are 1 cm for the ﬁrst 10 and last 10 leaves, and 0.5 cm for
the middle 40 leaves. Leaf pair number Lnum is calculated from w as:







intððt 1Þ=2Þ þ 1 t 2 ½1;20
t 10 t 2 ½21;60
intððt 61Þ=2Þ þ 51 t 2 ½61;80
8<
: (5)
where “int” denotes the integer conversion operation. The point r~ is
considered to be in the beam aperture if u is between the two leaf
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positions for the relevant leaf pair Lnum and within the beam opening
of the X and Y jaws.









where k is the control point index and DMUk is the beam MU allo-
cated between control points k and k+1. The rotation angles used in
the calculation of r~0 are the averaged values between points k and
k + 1. Likewise, the planned source position s~ is averaged between
points k and k + 1 as:
S~¼ ðSk~ þ S~k þ 1Þ=2 (7)
2.3 | Implementation details
The number of control points in VMAT plans is usually far less than
the number of records in the machine logs. A single 360° arc with a
total of 91 control points (4° per control point) within its associated
plan will be delivered in 2 min. Over this duration over 5000 log
records will be generated. With an angular sampling frequency of 4°
per beam in the plan, the reconstructed 3D ﬂuence volume will have
apparent alias; however, the delivery machine linearly interpolates
the beam parameters between control points in order to smooth the
expected delivered 3D ﬂuence. To calculate the 3D ﬂuence with
high accuracy, the control points in the DICOM plans thus need to
be up-sampled accordingly.17 It was empirically determined that 1°
per control point sufﬁciently reduces alias artifacts.
On the other hand, Varian TrueBeam machines create delivery
records every 20 ms with an equivalent angular resolution of 0.048°.
Because such high angular resolution is not necessary for detecting
gross delivery errors, machine logs are down-sampled by a factor of
16 to improve computation speed. To combine multiple records into
1 segment, the MLC leaf positions and gantry angles are averaged
and the beams MUs are summed.
The reconstruction volumes are automatically determined using
the maximal jaw opening from the treatment plan (plus a 1 cm margin)
given that the jaw positions are not changing during VMAT delivery. A
voxel size of 3 9 3 9 3 mm3 and 1 degree angular resolution are used
in this study in order to provide adequate spatial resolution for error
detection with high ﬁdelity and reasonable computation time.
2.4 | 3DFC QA for treatment delivery veriﬁcation
Figure 1 presents the general workﬂow of VMAT and IMRT 3DFC
QA, which can be described in details as follows:
1. Obtaining the treatment plan and the machine delivery logs.
2. Calculating the planned and delivered 3D ﬂuences from the
DICOM plan delivery logs using the 3D ﬂuence calculation
method.
3. Performing an intensity difference test (3%) and gamma analysis
(3%, 3 mm) between the planned and delivered ﬂuence values32–35
and computing the failing rates of both criteria, respectively.
4. Generating QA reports for physicists’ analysis and approval.
5. Intervening based on failing rates (according to the discretion of
a physicist).
A 3% intensity difference and 3%, 3 mm gamma criterion32–35
are chosen for deﬁning passing rates based on 3DFC comparisons.
In the 3% ﬂuence difference test, each voxel in the planned ﬂuence
map is considered to have passed if the ﬂuence difference between
planned and delivered values on the voxel is less than 3% of the
maximal intensity value. Voxels with intensity values smaller than
10% of the maximal value are excluded from analysis. The failing
rates of both tests summarize the total number of voxels that fail
the corresponding criterion out of the total number of voxels in the
ﬂuence map. The chosen parameters for the criteria (3% for ﬂuence
difference and 3%, 3 mm in the gamma analysis) are selected empiri-
cally in order to avoid excessive false positives while preserving suf-
ﬁcient sensitivity to catch major delivery errors.
Interventions of medical physicists are decided according to the
estimated failing rates of the two criteria. For instance, for a lung cancer
patient with up to 2 mm in simulated random MLC errors, the failing
rate of the 3% ﬂuence difference test was calculated to be 4.8%, and
the failing rate in gamma analysis (3%, 3mm) was 4.1%. For a heart
patient with up to 1° random gantry angle errors, the failing rate of the
ﬂuence difference test was calculated to be 2.4%, and the failing rate in
gamma analysis was 0.8%. While the threshold values for the action
levels should be determined with further clinical measurements and
judgments, which could be treatment site dependent, the general
threshold used in the authors’ clinic is 5% failing rate on 3%, 3 mm
gamma analysis. If the failing rate of gamma analysis is greater than 5%,
medical physicists should initiate further investigation.
2.5 | Testing with simulated delivery errors
In order to evaluate the capabilities of the 3DFC QA to detect deliv-
ery problems, we simulate ﬁve types of important machine parame-
ter errors by modifying the treatment plans (easier to modify than
log ﬁles) and comparing the detection results with both 2DFC QA
methods and conventional measurement-based QA using ArcCHECK
(Sun Nuclear Corp, Melbourne, FL, USA). We use the original
TAB L E 1 Normal tolerances and statistical distributions for various sources of errors of the Varian LINAC machines installed in our clinic.
Errors Gantry MU Jaw Collimator MLC
Tolerance 1° 1 MU 1 mm 1° 2 mm
Distribution Uniformly Uniformly Uniformly Uniformly Gaussian
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unmodiﬁed treatment plan to deliver the VMAT beams such that the
machine log ﬁle is recorded from the original plan delivery. Assuming
the modiﬁed plan is the correct plan, errors within the ﬂuence vol-
ume will be identiﬁed between the delivery log (from the original
unmodiﬁed plan) and modiﬁed plan (with simulated errors). Testing
of the simulated delivery errors includes two steps:
1. Simulation of gantry rotation errors, MU errors, jaw positions
errors, collimator rotation errors, and MLC leaf errors by adding
random values to the corresponding planned quantities per con-
trol point. These random artiﬁcial errors are speciﬁed according
to their corresponding statistical distributions and range well
within the corresponding error tolerances for the associated
parameters (as enumerated in Table 1).
2. Simulation of the errors enumerated above beyond their toler-
ances, including adding random values between 1° and 2° per
control point to both the planned gantry rotation angles and col-
limator rotation angles, adding random values between 1 and
2 MU per control point to planned MU values, adding random
values between 1 mm and 2 mm to planned jaw positions, and
shifting random values between 2 mm and 3 mm to either direc-
tion of the MLC leaf positions.
The tolerances of beam delivery parameters listed in Table 1 are
chosen based on the AAPM Task Group 142 report.36 Furthermore,
the statistical distributions of these types of errors are chosen based
on both the uncertainties of our machines and study reported in
Ref.18 Our goal is to test if the 3DFC is useful to detect errors that
are otherwise undetectable by value-to-value comparisons of beam
parameters, and to also investigate our method’s performance in
identifying errors beyond normal tolerances. For each VMAT plan,
the types of errors listed above are added one-by-one to the origi-
nal plan. A total of 10 error-introduced plans are thus created with
ﬁve incorporating errors within tolerance and ﬁve simulating errors
out of tolerance. The calculated ﬂuences of all plans will then be
compared with the delivery log ﬁle recorded from the original,
unmodiﬁed plan delivery. The passing rates of the 3% intensity dif-
ference test and 3%, 3 mm gamma analysis are used to evaluate the
detection performance (sensitivity) of the 3DFC QA for each type
of delivery error. Then, the QA results will be compared with the
performance of the 2DFC QA (with the composite 2D ﬂuence being
computed by ﬁxing the gantry angle at 0°), and with the perfor-
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F I G . 2 . The diagram of the correlation study design between the 3DFC QA and the measurement-based QA.
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2.6 | Correlation study design
In order to evaluate the capabilities of the 3DFC QA to detect dose
delivery errors, we quantitatively study the correlation between pass-
ing rates derived from ﬂuence maps and those observed on dose
measurements. Figure 2 schematically illustrates our correlation study
design. Adding the same types of simulated errors to the DICOM
plan (presented in Section 2.5), within their corresponding error toler-
ances, we calculate 3D ﬂuences, calculate 3D doses within the Pinna-
cle TPS (Phillips, Pinnacle), and measure 2D composite doses using
ArcCHECK, for both the original and modiﬁed plans. For each set of
calculated ﬂuences, calculated doses, and measured doses, we per-
form both an intensity difference test and gamma analysis test in
order to evaluate the differences between the original plan and the
error-introduced plans. Finally, a correlation study is conducted on
the resultant passing rates, between the ﬂuence and the calculated
dose, and between the ﬂuence and the measured dose.
The notation shown in Fig. 2 can be summarized as follows: Φ
denotes ﬂuence, D denotes dose, and P denotes passing rate. The
subscript c represents quantities derived from calculation, while the
subscript m represents quantities obtained from measurement. The
superscript 0 indicates an error-introduced plan (with the quantities
pertaining to the original plan not including a superscript). PIðr~Þ
describes the passing rates of the intensity difference test and Pc
describes the passing rates of gamma analysis.
In our correlation study, dose was inferred from both dose calcu-
lation within the TPS and measurement with ArcCHECK. Calculated
dose from the TPS provides 3D dose volumes thus allowing for QA
in 3D, while the measurement-based QA could only be in 2D and is
relatively sensitive to setup errors. After delivery, the measured 2D
dose volumes, denoted by Dm and D0m, respectively, are exported
from the ArcCHECK software for evaluations. The measured doses
D0m from each error-introduced plan are compared with the planned
calculated dose from TPS (Pinnacle), i.e., Dc.
For the passing rate results, we evaluate differences between: (1)
calculated 3D ﬂuences Φc and U
0
c; (2) calculated 3D planned doses
Dc and D0c; and (3) measured doses in phantom D
0
m and calculated
doses Dc. 2% and 2%, 2 mm criteria are used in the intensity differ-
ence tests and gamma analysis for evaluating differences in (1) and
(2), while 3% and 3%, 3 mm are chosen for evaluating differences in
(3). The 2% and 2%, 2 mm criteria for (1) and (2) were selected
empirically (similarly to the criteria choice for (3), as discussed previ-
ously). Furthermore, for (1) and (2), machine systemic errors, e.g.,
setup errors, are not included. Therefore, tighter constraints with
2%, rather than the 3% difference test and 3%, 3 mm gamma analy-
sis are applied in the ﬁrst two cases (1) and (2).
Finally, we obtain three groups of resultant passing rates with
each group consisting of two test results from both evaluation meth-
ods, denoted by PU;Iðr~Þ and PΦ,c, PDC;Iðr~Þ and PDC,c, and PDm;Iðr~Þ and
PDC,c. Five passing rates for each plan from ﬁve types of errors are
obtained for these three result groups. Both Pearson’s and Spear-
man’s correlation coefﬁcients are used to investigate the relation-
ships between groups of passing rates. In particular, r-values
(Pearson’s correlation coefﬁcient) and q-value (Spearman’s correla-
tion coefﬁcients) are calculated to measure the extent to which two
variables (e.g., PU;Iðr~Þ and PDC;Iðr~Þ) tend to change together, including
both the strength and the direction of the correlation.
3 | RESULTS
3.1 | Clinical results
This reported 3DFC QA method has also been applied to QA at
the authors’ institution for IMRT and VMAT treatments for the
past 4 + yr. For pre-treatment patient-speciﬁc QA prior to 2014, a
combination of ion chamber measurements (two points in a cus-
tomized cubic solid water phantom), MapCheck QA (per beam at a
ﬁxed gantry angle of 0°), and ﬂuence QA (using the log ﬁles
acquired in delivery for ion chamber measurements) were applied.
Since 2014, a combination of MatriXX QA (planar composite dose
measurement of all beams in the coronal plan at isocenter, mea-
sured in the standard MatriXX iso-cube water phantom) and ﬂu-
ence QA (log ﬁles acquired in the MatriXX QA delivery) have been
used, with the MatriXX QA replacing both ion chamber and per-
beam MapCheck measurements. 2DFC QA, which was developed
prior to the clinical implementation of VMAT, is applied to all
IMRT plans. 3DFC QA, which was developed particularly for VMAT
delivery veriﬁcation, is applied to VMAT beams. 3DFC QA is cur-
rently not applied to IMRT plans, not because of technical limita-
tions but rather for the sake of continuity in our institution’s
patient-speciﬁc plan QA paradigm. 2D and 3D ﬂuence-based QA
are implemented together with beam parameter checks in a fully
automated treatment delivery veriﬁcation program that is scheduled
to run every morning to automatically check all treatment deliver-
ies of the previous day and to alert physicists of any treatment
delivery issues.
From 2014 to date, 139 VMAT treatments were veriﬁed using
the reported 3DFC QA method (130 lung cancer patients, 5 heart
cancer patients, 3 brain cancer patients, and 1 spine patient). Screen-
shots of this QA software and associated QA reports are illustrated
in (Fig. 3) for one lung patient treated in 2015.
The reported 3DFC QA method was implemented in MATLAB
2012a (Mathworks, Natick, MA, USA). The computational accuracy
and speed were tested for different choices of parameters. Voxel
sizes and angular resolutions of 3 9 3 9 3 cm3 and 1° were ulti-
mately chosen for 3D ﬂuence calculations of both treatment plans
and log records in order to obtain satisfactory spatial resolution and
computation speed. Computation time ranges between 10 and
30 seconds per patient, with the speed ultimately depending on the
number of VMAT beams and the size of the treatment target.
3.2 | Lung plan
As lung patients are the most common VMAT-treated patients in
our clinic, we present one example of the delivery QA results
including both the 3D and 2D ﬂuences, using a four-arc right lung
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VMAT plan with a total of 4328 MU. Figure 3 shows both the cal-
culated 3D and 2D ﬂuences integrated over the four arcs on the
ﬁrst two rows, including results obtained from both the DICOM
plan and the log ﬁle, respectively. The corresponding calculated ﬂu-
ence map differences are shown on the third row. The 3D ﬂuence vol-
umes with PTV contours drawn are illustrated in axial, coronal, and
sagittal views in the ﬁrst three columns, respectively, while the 2D ﬂu-
ence (computed by forcing gantry angle = 0) is illustrated in the fourth
column. Gantry angle, collimator, jaw, and MLC positions were all within
allowed clinical tolerances during actual delivery. 3D ﬂuence errors are
1.3  1.1 MU and the maximal ﬂuence error is 10.1 MU (0% failing
rates for both criteria are found). As can be seen, there are only minimal
ﬂuence differences between the plan and delivery logs. More impor-
tantly, 3D ﬂuence maps provide a signiﬁcantly improved visualization in
multiple orthogonal views on the PTV than the 2D map which cannot
be associated with the PTV 3D shape.
3.3 | Simulated delivery error results and analysis
As described in Section 2.5, we ﬁrst simulated different types of
machine errors per control point within normal machine tolerances.
A total number of 10 patients with ﬁve lung (4-arc) and ﬁve heart
(3-arc) VMAT plans were tested for simulated delivery errors. Results
of averaged (mean value) failing rates for the 3% intensity ﬂuence
difference test and 3%, 3 mm gamma analysis, denoted by FIðr~Þ;3%
and Fc,3%,3mm respectively, are presented in (Table 2). For instance,
using the 3DFC method, random gantry angle errors up to 1° could
cause mean values of 7.4% and 6.2% of voxels to fail the 3% inten-
sity difference test and 3%, 3 mm gamma analysis, respectively. In
contrast, these simulated gantry angle errors were never detected by
2D ﬂuence calculations because gantry angles are not used. Based
on these results shown in Table 2, we may therefore conclude that
the 3DFC QA method is more sensitive in detecting gantry angle
errors, MU errors, jaw position errors, and collimator rotation errors
than 2D ﬂuence method.
As also summarized in Table 2, we tested both algorithms upon
adding simulated 1-2 mm random MLC errors. We only adjusted the
position of leaves that actually contribute to ﬂuence during delivery.
As one can see, both 3D and 2D methods are very sensitive to MLC
position errors. However, the results suggest that the 3DFC QA
method is less sensitive to MLC positional errors than the 2D
method. This might be due to that MLC positional errors only affect
the beam ﬂuence at the edges but not inside of beam portals. Arc-
CHECK measurements were performed on these unmodiﬁed VMAT
3D – axial view 3D – coronal view 3D – sagittal view 2D
F I G . 3 . Results of 3D and 2D ﬂuences from a four-arc lung VMAT plan. Top row is from the DICOM plan. Middle row is from the log ﬁle.
Bottom row is obtained by calculating the corresponding ﬂuence differences. The PTV contours in the respective 3D orthogonal views are
overlaid on the 3D ﬂuences.
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test plans. For each plan, the measured dose will be compared with
10 calculated dose ﬁles from error-introduced plans (see Sec-
tion 2.5). Results presented in (Table 2) show that 3DFC QA is more
sensitive to these simulated machine errors than the conventional
measurement-based QA.
Furthermore, simulated errors outside their corresponding normal
tolerances are tested. Signiﬁcantly greater errors are found in this
case which demonstrates both the conclusion on 3DFC method
achieving better sensitivity than the 2DFC. Two examples of the cal-
culated 3D ﬂuence differences in axial views are illustrated in
TAB L E 2 QA results with simulated delivery errors.
Simulated errors
3D Fluence 2D Fluence 2D Measurement
FIðr~Þ;3% Fc,3%,3mm FIðr~Þ;3% Fc,3%,3mm FIðr~Þ;3% Fc,3%,3mm
Errors within machine tolerance
Gantry 7.4% 6.2% 0% 0% 2.3% 1.4%
MU 1.2% 0.5% 0% 0% 0.7% 0%
Jaw 2.7% 1.6% 0.2% 0% 2.5% 0.2%
Collimator 1.6% 0.6% 0.3% 0% 0% 0%
MLC 14.3% 6.2% 21.1% 11.0% 13.5% 5.9%
Errors outside machine tolerance
Gantry 14.1% 10.3% 3.3% 2.7% 11.5% 4.6%
MU 51.5% 37.7% 43.3% 24.2% 47.1% 36.9%
Jaw 11.6% 4.2% 4.8% 2.3% 5.2% 2.6%
Collimator 12.5% 7.3% 4.1% 9.3% 10.4% 3.5%
MLC 26.3% 9.3% 38.9% 24.7% 22.1% 5.9%
(a) (b)
(c) (d)
FI(r),3% = 8.7%← FI(r),3% = 19.5%←
FI(r),3% = 42.5%← FI(r),3% = 38.7%←
F I G . 4 . The axial views of ﬂuence differences generating by simulated errors: (a) with ﬁxed 1° gantry angle errors; (b) with ﬁxed 2 mm
shifting MLC leaf position errors; (c) 90% of the plan is interrupted during delivery; and (d) an incorrect version of the plan is delivered.
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(Fig. 4), where (a) is generated using ﬁxed 1° gantry angle error in
one lung plan, and (b) is generated with ﬁxed 2 mm MLC position
errors in the same lung plan. These artiﬁcial errors can be visually
seen in the 3D ﬂuence difference map, which also suggest the feasi-
bility of our method.
Figure 4 also illustrates two 3D ﬂuence difference maps gener-
ated by simulating two common clinical events: interruptive deliv-
ery with 10% of the control points left out during treatment, and
delivering the wrong version of the plan (of another lung patient
used).
In order to better understand the relationship between the deliv-
ery errors and the performance of the 3DFC QA method, different
values of artiﬁcial errors for each error type are added into each
control point and the corresponding average (mean value) failing
rates of the 3D ﬂuence difference test (3%) are obtained for these
10 VMAT plans. Figure 5 shows plots of the correlations between
the normalized simulated errors and the failing rates both in percent-
ages for all the error types examined in this paper, while results of
the reported 3DFC QA (in solid lines) are compared with those of
the 2D ﬂuence-based QA (in dashed lines). The generated errors are
normalized to the corresponding tolerance in percentage, for
instance, gantry angle errors are scaled to 100% at 1°. As can be
seen, failing rates start to climb much more quickly when the errors
lie outside their normal machine tolerances. It again demonstrates
the conclusion from Table 2 that 3DFC algorithm is more sensitive
to MU, jaw position, and collimator rotation errors than 2DFC, while
2DFC cannot catch gantry rotation errors.
3.4 | Correlation study results on ﬂuence vs. dose
and analysis
In the correlation study, 10 IMRT plans and 10 VMAT plans with
ﬁve different types of errors were used. Table 3 presents the com-
puted correlations between PU;Iðr~Þ and PDC;Iðr~Þ, and between PΦ,c and
PDC,c. Table 4 presents the computed correlation between PU;Iðr~Þ and
PDm;Iðr~Þ, and between PΦ,c and PDm,c. In both tables, the Spearman’s
correlation coefﬁcient q-value is signiﬁcantly closer to +1 than the
Pearson’s correlation coefﬁcient r-value. The p-values for all errors
types are smaller than the signiﬁcance level 5%, which suggest the
statistically signiﬁcant correlation. These results show that the
F I G . 5 . Correlations between the simulated errors and the 3% ﬂuence differences test failing rates for various types of errors using both
3DFC QA in solid lines and 2D ﬂuence QA in dashed lines.
TAB L E 3 Results of correlation coefﬁcients between PΦ and PDc
from all the error types.
Coefﬁcients Gantry MU Jaw Collimator MLC
PU;Iðr~Þ and PDc;Iðr~Þ (2% intensity difference)
Pearson (r) 0.5631 0.5489 0.7025 0.8575 0.5297
Spearman (q) 0.9267 0.9183 0.9226 0.9515 0.6754
Spearman (p) 0.0427 0.0242 0.0475 0 0.0305
PΦ,c and PDc,c (2%, 2mm Gamma analysis)
Pearson (r) 0.6125 0.5987 0.7871 0.8824 0.5011
Spearman (q) 0.9334 0.9423 0.9498 0.9817 0.7042
Spearman (p) 0.0375 0.0197 0.0420 0 0.0421
TAB L E 4 Results of correlation coefﬁcients between PΦ and PDm
from all the error types.
Coefﬁcients Gantry MU Jaw Collimator MLC
PU;Iðr~Þ and PDm;Iðr~Þ (3% intensity difference)
Pearson (r) 0.4121 0.6514 0.5248 0.8554 0.4336
Spearman (q) 0.9701 0.8997 0.9015 0.9810 0.7853
Spearman (p) 0.0232 0.0399 0.0425 0.0315 0.0652
PΦ,c and PDm,c (3%, 3mm Gamma analysis)
Pearson (r) 0.5771 0.5397 0.6541 0.7981 0.5026
Spearman (q) 0.8653 0.9012 0.9520 0.9805 0.7916
Spearman (p) 0.04196 0.0356 0.0492 0.0157 0.0694
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resultant passing rates indicated by 3DFC are correlated with the
passing rates speciﬁed by dose mapping, obtained from either calcu-
lation or measurement.
4 | DISCUSSION
3DFC QA is useful to detect relatively common treatment delivery
imperfections (e.g., imperfect deliveries due to the end effect for
highly modulated IMRT beams that deliver low MUs, and treatment
delivery interruptions). Although overall treatment delivery accuracy
has been signiﬁcantly improved by newer LINAC machines, e.g., Var-
ian’s TrueBeam, the reported 3DFC QA can serve as an additional
safeguard for error checking. Additionally, the reported method can
continue to provide QA for older, more error-prone machines.
Comparing to the previous treatment delivery log-based QA
methods, 3DFC QA is capable of presenting the QA results and the
computed beam ﬂuences in 3D geometry and therefore allows users
to easier interpret QA results in terms of the patient 3D anatomy
and the PTV target. In comparison to 2DFC (using composite ﬂuence
maps and ignoring gantry rotation), 3DFC QA can detect important
treatment delivery errors, such as gantry angle errors, and is more
sensitive to MU, jaw position, and collimator rotation errors. For the
case of MLC errors, even though the 3D method is less sensitive
than the 2D method, the sensitivity is sufﬁcient for the general
VMAT delivery veriﬁcation purpose. In comparison to other methods
that only check beam parameters in delivery log ﬁles, e.g., Frac-
tionCheck (Mobius Medical System, Houston, TX, USA), 3DFC com-
pares 3D ﬂuences derived from log ﬁles with those speciﬁed by the
treatment plans, thus enabling detection of frequently occurring
treatment plan data transfer errors (incorrect plan version, incorrect
version of the individual beams.11
The described 3DFC method is not designed to catch most
errors in treatment planning system, e.g., imperfect beam modeling.
Its primary application is instead to catch certain rare errors such as
the junctions of closed MLC leaf pairs left inside the beam ﬁeld
deﬁned by the X and Y jaws in Pinnacle step-and-shoot IMRT
plans.11 Compared to measurement-based QA, the results of 3DFC
QA are less independent because the beam parameters in the deliv-
eries were measured by the treatment machines instead by indepen-
dent measurement device. The beam output and the beam proﬁle
are not directly measured, either. The accuracy of the beam parame-
ters provided in the machine log ﬁles must be independently veriﬁed
through routine machine QA in order to be considered reliable. In
fact, in one reported incident MLC positions recorded in the log ﬁle
were shown to be inconsistent with observed, true positions.37
Therefore, concerns and debates continue on the merits of log-ﬁle
based QA.5 For these reasons, the reported 3DFC method is cur-
rently used as a complementary tool to measurement-based QA for
pre-treatment IMRT and VMAT patient-speciﬁc QA in our clinic.
Once conﬁdence has been established via pre-treatment QA derived
from calculation and measurement, 3DFC is used to verify the sub-
sequent patient treatment deliveries.
3DFC is also not designed to replace a full dose calculation, but as
an alternative approach as a delivery QA with enhanced visualization
and error sensitivity, focusing directly on checking machine parame-
ters. Comparing to full 3D dose calculation methods, 3DFC ignores
many important physical effects including phantom scattering and
attenuation. However, 3DFC is simpler and could be potentially much
faster. The current computation speed, 3 to 20 seconds per VMAT
beam, accomplished with MATLAB programs could also be signiﬁ-
cantly improved when 3DFC is reimplemented in C/C++ or GPU pro-
grams. It might be worth to note that the computation speed of
3DFC is sufﬁcient for clinical use without GPU acceleration. This
allows the reported QA method to be more clinically deployable with-
out the need of relatively expensive GPU hardware. As shown in (Sec-
tion 3.4), 3DFC passing rates are correlated with passing rates
inferred from measurement-based QA. The correlation results could
be interpreted as a monotonic trend observed for the two obtained
passing rates, i.e., ﬂuence vs. dose, where higher ﬂuence errors indi-
cates higher dose errors, and lower ﬂuence errors indicates lower
dose errors. Given the same error type and threshold, the 20 observa-
tions (i.e., passing rates) obtained for both QA methods can be consid-
ered as two ranked variables in the Spearman’s correlation, which is
proven to be much stronger than Pearson’s linear relationship.
Even though the reported 3DFC method digitally reconstructs 3D
ﬂuence from the treatment plan and treatment delivery logs, 3D ﬂuence
can be also reconstructed from measured 2D ﬂuence using 2D diode







where G is a frame of the measured ﬂuence map movie, Dt is the
measurement repetition period. Beam MU is not in this equation be-
cause it is reﬂected by the intensity of measured beam ﬂuence. Gan-
try angles must be simultaneously measured.
5 | CONCLUSION
An efﬁcient method, 3DFC, has been developed to calculate 3D ﬂu-
ence volumes using the beam parameters from both DICOM plan
ﬁles and machine delivery log ﬁles for verifying both IMRT and
VMAT treatment deliveries. This method is designed to work com-
plementarily to other QA procedures including dose recalculations
and phantom-based measurements in order to provide a quick and
easy measurement of beam delivery ﬁdelity and better visual presen-
tation of delivery errors in 3D. The reported method could be useful
in catching both treatment plan data transfer errors and treatment
delivery problems.
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